Oruka Therapeutics (ORKA) Stock Forecast & Price Target

Compare

745 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ORKA Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Oruka

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ORKA Stock 12 Month Forecast

Average Price Target

$60.71

▲(87.72% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Oruka Therapeutics in the last 3 months. The average price target is $60.71 with a high forecast of $75.00 and a low forecast of $40.00. The average price target represents a 87.72% change from the last price of $32.34.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","25":"$25","42":"$42","59":"$59","76":"$76"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$60.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,25,42,59,76],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.3,37.43076923076923,40.56153846153846,43.69230769230769,46.823076923076925,49.95384615384616,53.08461538461538,56.215384615384615,59.34615384615385,62.47692307692308,65.6076923076923,68.73846153846154,71.86923076923077,{"y":75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.3,36.33153846153846,38.36307692307692,40.394615384615385,42.426153846153845,44.457692307692305,46.48923076923077,48.52076923076923,50.55230769230769,52.58384615384615,54.61538461538461,56.64692307692308,58.67846153846154,{"y":60.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.3,34.738461538461536,35.176923076923075,35.61538461538461,36.05384615384615,36.49230769230769,36.93076923076923,37.36923076923077,37.80769230769231,38.246153846153845,38.684615384615384,39.12307692307692,39.56153846153846,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.45,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.09,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.77,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.56,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.62,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.17,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.67,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.31,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.3,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$75.00

Average Price Target$60.71

Lowest Price Target$40.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Sam Slutsky

LifeSci Capital

$71

Buy

119.54%

Upside

Reiterated

02/09/26

Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Centene (CNC)

Yasmeen Rahimi

Piper Sandler

$75

Buy

131.91%

Upside

Reiterated

02/05/26

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), 10x Genomics (NASDAQ: TXG) and Oruka Therapeutics (NASDAQ: ORKA)

Julian Harrison

BTIG

$63→$73

Buy

125.73%

Upside

Reiterated

02/02/26

BTIG Sticks to Its Buy Rating for Oruka Therapeutics (ORKA)

Mitchell Kapoor

H.C. Wainwright

$40

Buy

23.69%

Upside

Reiterated

01/21/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Martin Fan

Wedbush

$42→$45

Buy

39.15%

Upside

Reiterated

01/13/26

Oruka Therapeutics price target raised to $45 from $42 at WedbushOruka Therapeutics price target raised to $45 from $42 at Wedbush

Kaveri Pohlman

Clear Street

$46→$71

Buy

119.54%

Upside

Reiterated

01/13/26

Oruka Therapeutics price target raised to $71 from $46 at Clear StreetOruka Therapeutics price target raised to $71 from $46 at Clear Street

Michael Yee

UBS

$50

Buy

54.61%

Upside

Initiated

01/06/26

Oruka Therapeutics initiated with a Buy at UBSOruka Therapeutics initiated with a Buy at UBS

Roger Song

Jefferies

$45

Buy

39.15%

Upside

Reiterated

11/19/25

Jefferies Sticks to Its Buy Rating for Oruka Therapeutics (ORKA)

Etzer Darout

Barclays

$48

Buy

48.42%

Upside

Reiterated

11/13/25

Oruka Therapeutics (ORKA) Gets a Buy from Barclays

Yatin Suneja

Guggenheim

$60

Buy

85.53%

Upside

Reiterated

11/13/25

Guggenheim Reaffirms Their Buy Rating on Oruka Therapeutics (ORKA)

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

11/12/25

Oruka Therapeutics: Promising Advancements in Monoclonal Antibodies Drive Buy Rating

David Risinger

Leerink Partners

―

Buy

―

Reiterated

10/08/25

Leerink Partners Sticks to Its Buy Rating for Oruka Therapeutics (ORKA)

Alex Thompson CFA

Stifel Nicolaus

$47

Buy

45.33%

Upside

Reiterated

07/28/25

Oruka Therapeutics (ORKA) Receives a Buy from Stifel Nicolaus

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Sam Slutsky

LifeSci Capital

$71

Buy

119.54%

Upside

Reiterated

02/09/26

Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Centene (CNC)

Yasmeen Rahimi

Piper Sandler

$75

Buy

131.91%

Upside

Reiterated

02/05/26

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), 10x Genomics (NASDAQ: TXG) and Oruka Therapeutics (NASDAQ: ORKA)

Julian Harrison

BTIG

$63→$73

Buy

125.73%

Upside

Reiterated

02/02/26

BTIG Sticks to Its Buy Rating for Oruka Therapeutics (ORKA)

Mitchell Kapoor

H.C. Wainwright

$40

Buy

23.69%

Upside

Reiterated

01/21/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Martin Fan

Wedbush

$42→$45

Buy

39.15%

Upside

Reiterated

01/13/26

Oruka Therapeutics price target raised to $45 from $42 at WedbushOruka Therapeutics price target raised to $45 from $42 at Wedbush

Kaveri Pohlman

Clear Street

$46→$71

Buy

119.54%

Upside

Reiterated

01/13/26

Oruka Therapeutics price target raised to $71 from $46 at Clear StreetOruka Therapeutics price target raised to $71 from $46 at Clear Street

Michael Yee

UBS

$50

Buy

54.61%

Upside

Initiated

01/06/26

Oruka Therapeutics initiated with a Buy at UBSOruka Therapeutics initiated with a Buy at UBS

Roger Song

Jefferies

$45

Buy

39.15%

Upside

Reiterated

11/19/25

Jefferies Sticks to Its Buy Rating for Oruka Therapeutics (ORKA)

Etzer Darout

Barclays

$48

Buy

48.42%

Upside

Reiterated

11/13/25

Oruka Therapeutics (ORKA) Gets a Buy from Barclays

Yatin Suneja

Guggenheim

$60

Buy

85.53%

Upside

Reiterated

11/13/25

Guggenheim Reaffirms Their Buy Rating on Oruka Therapeutics (ORKA)

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

11/12/25

Oruka Therapeutics: Promising Advancements in Monoclonal Antibodies Drive Buy Rating

David Risinger

Leerink Partners

―

Buy

―

Reiterated

10/08/25

Leerink Partners Sticks to Its Buy Rating for Oruka Therapeutics (ORKA)

Alex Thompson CFA

Stifel Nicolaus

$47

Buy

45.33%

Upside

Reiterated

07/28/25

Oruka Therapeutics (ORKA) Receives a Buy from Stifel Nicolaus

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Oruka Therapeutics

3 Months

xxx

Success Rate

6/7 ratings generated profit

Average Return

+50.04%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 85.71% of your transactions generating a profit, with an average return of +50.04% per trade.

1 Year

David RisingerLeerink Partners

Success Rate

8/9 ratings generated profit

Average Return

+119.99%

reiterated a buy rating 5 months ago

Copying David Risinger's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +119.99% per trade.

2 Years

xxx

Success Rate

9/9 ratings generated profit

Average Return

+127.79%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +127.79% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ORKA Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ORKA has received 12 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ORKA average Analyst price target in the past 3 months is 60.71.

Each month's total comprises the sum of three months' worth of ratings.

ORKA Financial Forecast

ORKA Earnings Forecast

Next quarter’s earnings estimate for ORKA is -$0.64 with a range of -$0.85 to -$0.49. The previous quarter’s EPS was -$0.55. ORKA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year ORKA has Performed in-line its overall industry.

No data currently available

ORKA Sales Forecast

Next quarter’s sales forecast for ORKA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ORKA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year ORKA has Performed in-line its overall industry.

ORKA Stock Forecast FAQ

What is ORKA’s average 12-month price target, according to analysts?

Based on analyst ratings, Oruka Therapeutics’s 12-month average price target is 60.71.

What is ORKA’s upside potential, based on the analysts’ average price target?

Oruka Therapeutics has 87.72% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ORKA a Buy, Sell or Hold?

Oruka Therapeutics has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is Oruka Therapeutics’s price target?

The average price target for Oruka Therapeutics is 60.71. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $75.00 ,the lowest forecast is $40.00. The average price target represents 87.72% Increase from the current price of $32.34.

What do analysts say about Oruka Therapeutics?

Oruka Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of ORKA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Oruka Therapeutics (ORKA) Stock Forecast & Price Target

ORKA Analyst Ratings

ORKA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Oruka Therapeutics

ORKA Analyst Recommendation Trends

ORKA Financial Forecast

ORKA Earnings Forecast

ORKA Sales Forecast

ORKA Stock Forecast FAQ

Detailed List of Analyst Forecasts